DYOR. Not advice. Analysis is highly-speculative.Here's a scenario for a royalty model, where RAC develops Bisantrene in consultation with a partner that does the marketing and sales.
These are the main differences in assumptions used:
I think this is a higher-risk proposition for RACE and that it will take more time for ramp-up of treatments to patients.
- Assumed fully-diluted share issue 250M shares (current is approximately 156M and I used 200M in buyout scenarios). Reasoning for this is increased investment that might be required by RACE.
- 20% royalty on sales for AML and Ovarian Cancer as these are smaller indications
- 15% royalty on sales for Breast Cancer
- Increased after-tax margin to 20% (this is RACE's assumed after-tax margin as a proportion of total their net revenue from a royalty received from a partner)
- I have done share price projections at 22.48 (pharma industry average) and a more bullish 30.0.
Note - the revenue line is peak revenue at year 7 of commercialisation. So could take several years for 5+ years for share prices.
Lol - spilit offee o y wireless keyoard. ight eed to let it dry. Sees to e the otto row that is the aily affeted. If there are ay errors the I a laig the keyoard
DYOR. Not advice. Analysis is highly-speculative. Here's a...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.030(2.52%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $78.70K | 66.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 4561 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.19 | $1.22 | $1.16 | 11297 | ||
| Last updated 15.56pm 07/05/2024 ? | |||||
| RAC (ASX) Chart |